Clinical Trials Sponsored by CTU

Total 979 results

CTU

Completed

Comparison of Two Dose Regimens of Snake Antivenom for the Treatment of Snake Bites Envenoming in Nepal

Snake Bite

Nepal
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
CTI BioPharma

Terminated

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Prostate Cancer

United States
CTI BioPharma

Withdrawn

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

NSCLC

United States
CTI BioPharma

Withdrawn

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Non-Hodgkin's Lymphoma

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Follicular | Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade

United States
CTI BioPharma

Completed

Phase II CT-2103/Carboplatin in Ovarian Cancer

Ovarian Neoplasm

United States
CTI BioPharma

Completed

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
CTI BioPharma

Terminated

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (PIONEER)

NSCLC

United States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
CTI BioPharma

Terminated

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Canada, United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
CTI BioPharma

Completed

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (RAPID)

Diffuse Large-Cell Lymphoma

United States, Germany, Canada, Italy, France
CTI BioPharma

Completed

Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer

Colorectal Cancer

Italy
CTI BioPharma

Withdrawn

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment (Hepatic)

Metastatic Cancer

United States
CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
CTI BioPharma

Withdrawn

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma | Leukemia

United States
CTI BioPharma

Terminated

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
CTI BioPharma

Withdrawn

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Lymphoma | Solid Tumor (Excluding CNS)

United States
CTI BioPharma

Completed

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic

United States
CTI BioPharma

Completed

CT-2106 for the Second Line Treatment of Ovarian Cancer

Ovarian Cancer

France, United Kingdom, Italy
CHU de Reims

Recruiting

Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France (PREDDICHA)

Primary Immunodeficiency | Common Variable Immunodeficiency | Igg Subclass Deficiency | Selective IgM Deficiency

France
CHU de Reims

Not yet recruiting

Superiority Randomized Controlled Trial of Ultrasound-guided PENG Block Compared to Surgical Infiltration in the Analgesia of Posterior Total Hip Arthroplasty Surgery (PENGORINF)

Hip Arthrosis | Hip Arthropathy

France
CHU de Reims

Recruiting

New Cognitive Treatment for Peripartum Depression (MCT-DPP)

Postnatal Depression

France
CHU de Reims

Not yet recruiting

Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis (BAC-Reims)

Adhesive Capsulitis

France
CHU de Reims

Recruiting

Intraoral Scanners as Periodontal and Dental Pathologies Diagnosis Tools (Odonto3D)

Periodontitis | Gingivitis | Dental Caries | Diagnosis

France
CTI BioPharma
PPD

Recruiting

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Hepatic Impairment

United States
CHU de Reims

Not yet recruiting

Withholding or Withdrawing of Life-sustaining Therapy in Great East French Region Intensive Care Units: a 1-month Survey (LATA)

Intensive Care Units | Family's Satisfaction | Therapy Decisions

France
CHU de Reims

Recruiting

Cardiac Amyloidosis Prevalence and Outcome in Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Implantation (CAMPOS-TAVI)

Aortic Stenosis

France
CHU de Reims

Recruiting

Comparison of HYDROLINK™ and HeprAN™ mEmbranes in a Per Dialytic Heparin Weaning Strategy in Chronic Hemodialysis Patients (RESTIT)

Renal Insufficiency

France
CHU de Reims

Not yet recruiting

Intraoral Scanners as a Motivation Method for Oral Hygiene Instruction (Perio3D)

Periodontitis | Gingivitis

France
CHU de Reims

Not yet recruiting

History of Exposure to Endocrine Disruptors in Women With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome | Exposure to Endocrine Disruptors

France
CHU de Reims

Recruiting

Social Cognition and Executive Functions in Alcohol Use Disorders - Transverse Study (COSEFEX-T)

Alcohol Use Disorder

France
CHU de Reims

Recruiting

Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma (PESTIPAC)

Carcinoma | Pancreatic Ductal

France
CHU de Reims

Recruiting

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

Diabetic Retinopathy | Retinal Vein Occlusion

France
CHU de Reims

Recruiting

Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer (AgElOn)

Cancer

France
CHU de Reims

Active, not recruiting

Autoantibodies Prevalence During Checkpoint Inhibitor Treatment

Autoimmune Adverse Effects of Anti-neoplasic Drug

France
CTI BioPharma
PPD

Completed

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Drug Interactions

United States
CHU de Reims

Completed

Validation of the French Version of the Xerostomia Inventory (XIvf)

Xerostomia

France
CHU de Reims

Completed

Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer (CAPANCOVID-19)

Pancreatic Adenocarcinoma

France
CTI BioPharma
Covance

Completed

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

Healthy

United States
CHU de Reims

Completed

Efficacy and Safety of Ustekinumab in Bullous Pemphigoid (PB-USTE)

Bullous Pemphigoid

France
CHU de Reims

Completed

Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital

Kidney Transplant Infection

France
CHU de Reims

Completed

Diabetes Mellitus and Pregnancy : Knowledge Assessment (DMPKA)

Diabetes Mellitus

France
CHU de Reims

Completed

Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study (AMIDIAL-ICU)

Amikacin Treatment

France

3

Subscribe